Brokerages Anticipate Cardlytics Inc (CDLX) Will Post Quarterly Sales of $43.77 Million

Brokerages predict that Cardlytics Inc (NASDAQ:CDLX) will post sales of $43.77 million for the current quarter, Zacks reports. Five analysts have provided estimates for Cardlytics’ earnings, with the highest sales estimate coming in at $44.70 million and the lowest estimate coming in at $43.10 million. Cardlytics posted sales of $35.57 million during the same quarter last year, which suggests a positive year over year growth rate of 23.1%. The business is scheduled to issue its next quarterly earnings results on Tuesday, August 13th.

According to Zacks, analysts expect that Cardlytics will report full-year sales of $187.37 million for the current year, with estimates ranging from $183.00 million to $195.00 million. For the next year, analysts forecast that the firm will post sales of $261.19 million, with estimates ranging from $246.80 million to $280.00 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Cardlytics.

Cardlytics (NASDAQ:CDLX) last announced its earnings results on Thursday, May 9th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.31. The business had revenue of $35.99 million during the quarter, compared to the consensus estimate of $36.11 million. Cardlytics had a negative net margin of 25.53% and a negative return on equity of 84.02%. Cardlytics’s revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.35) EPS.

Several brokerages recently commented on CDLX. Zacks Investment Research raised shares of Cardlytics from a “hold” rating to a “buy” rating and set a $22.00 target price for the company in a report on Thursday. SunTrust Banks reissued a “buy” rating and issued a $25.00 price objective on shares of Cardlytics in a report on Wednesday, March 6th. KeyCorp boosted their price objective on shares of Cardlytics from $25.00 to $26.00 and gave the company an “overweight” rating in a report on Friday, May 10th. Finally, ValuEngine downgraded shares of Cardlytics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 23rd. Eight equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $22.71.

Shares of CDLX stock traded down $0.40 during midday trading on Tuesday, hitting $19.70. 1,240 shares of the company were exchanged, compared to its average volume of 264,761. The company has a market capitalization of $452.97 million, a price-to-earnings ratio of -9.29 and a beta of 3.36. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.37 and a current ratio of 2.37. Cardlytics has a 52 week low of $9.80 and a 52 week high of $28.29.

In other news, insider Kirk Somers sold 2,508 shares of the company’s stock in a transaction that occurred on Friday, March 29th. The shares were sold at an average price of $16.20, for a total transaction of $40,629.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO David Thomas Evans sold 2,634 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $15.42, for a total transaction of $40,616.28. The disclosure for this sale can be found here. Insiders sold a total of 22,087 shares of company stock valued at $348,050 in the last three months.

Several institutional investors have recently modified their holdings of CDLX. Frontier Capital Management Co. LLC increased its position in Cardlytics by 105.6% during the 4th quarter. Frontier Capital Management Co. LLC now owns 1,462,777 shares of the company’s stock worth $15,842,000 after purchasing an additional 751,148 shares in the last quarter. Cannell Capital LLC acquired a new position in Cardlytics during the 4th quarter worth approximately $5,491,000. Jennison Associates LLC increased its position in Cardlytics by 58.3% during the 4th quarter. Jennison Associates LLC now owns 1,264,354 shares of the company’s stock worth $13,693,000 after purchasing an additional 465,855 shares in the last quarter. Wellington Management Group LLP increased its position in Cardlytics by 97.1% during the 1st quarter. Wellington Management Group LLP now owns 391,802 shares of the company’s stock worth $6,481,000 after purchasing an additional 193,050 shares in the last quarter. Finally, Penn Capital Management Co. Inc. acquired a new position in Cardlytics during the 4th quarter worth approximately $1,665,000. 73.34% of the stock is owned by institutional investors.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Read More: How is a Moving Average Calculated?

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.